HERG K+ channel, the target of anti-arrhythmias drugs

Yaoxue Xuebao

Volumn 42, Issue 7, 2007, Pages 687-691

  Guan, Feng Ying ^a   Yang, Shi Jie ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Cardiac arrhythmia; Drug treatment; HERG; Ikr; LQTS

Indexed keywords

ANTIARRHYTHMIC AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ARTICLE; CHANNEL GATING; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HEART ARRHYTHMIA; HUMAN; LONG QT SYNDROME; METABOLISM; MUTATION;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; ION CHANNEL GATING; LONG QT SYNDROME; MUTATION; POTASSIUM CHANNEL BLOCKERS;

EID: 34548450259     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Warmke JW, Ganetzky B, A family of potassium channel genes related to eag in Drosophila and mammals [J]. Proc Natl Acad Sci USA, 1994, 91:3438-3442.
2. + channel. Open-channel block by methanesulfonanilides [J]. Circ Res, 1996, 78:499-503.
3. Smith PL, Bankrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel [J]. Nature, 1996, 379:833-836.
4. + channel, a regulator of tumor cell apoptosis and proliferation [J]. Cancer Res. 2002, 62:4843-4848.
5. Zhou J, Meng R, Li XX, et al. The effect of arsenic trioxide on QT interval prolongation during APL therapy [J]. Chin Med J, 2003, 116:1764-1766.
6. Yang BF, Sun HL, Wang H, et al. The study on arsenic trioxide-induced QT interval prolongation and underlying ionic targets [J]. Chin J Endemiol, 2005, 24:488-490.
7. Ficker E, Kuryshev YA, Dennis AT, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization [J]. Mol Pharmacol, 2004, 66:33-44.
8. Kuryshev YA, Ficker E, Wang L, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking [J]. J Pharmacol Exp Ther, 2005, 312:316-323.
9. Cordes JS, Sun Z, Lloyd DB, et al. Pentamidine reduces hErg expression to prolong the QT interval [J]. Br J Pharmacol, 2005, 145:15-23.
10. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG [J]. Circulation, 2004, 109:30-35.
11. Schimpf R, Wolpert C, Gaita F, et al. Short QT syndrome [J]. Cardiovasc Res, 2005, 67:357-366.
12. Priori S, Napolitano C, Paganini V, et al. Molecular biology of the long QT syndrome: impact on management pacing [J]. Clin Eletrophysiol, 1997, 20:2052-2057.
13. Thomas D, Zhang W, Karle CA, et al. Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A [J]. J Biol Chem, 1999, 274:27457-27462.
14. + current is inhibited by betal-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways [J]. Cardiovasc Res, 2002, 53:355-362.
15. + currents via different signaling pathways in canine ventricular myocytes [J]. J Biol Chem, 2001, 276:40811-40816.
16. + channel function by hypoglycemia and hyperglycemia. Similar phenotypes but different mechanisms [J]. J Biol Chem, 2003, 278:10417-10426.
17. + channel function as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits [J]. Am J Physiol Heart Circ Physiol, 2006, 291:H1446-H1455.
18. + channel function by phospholipid metabolites [J]. Br J Pharmacol, 2004, 141:586-599.
19. +) channel function [J]. Circulation, 2001, 104:2645-2648.
20. Yang BF, Xu DH, Xu CQ, et al. Inactivation gating determines drug potency : a common mechanism for drug blockade of HERG channels [J]. Acta Pharmacol Sin, 2004, 25:554-560.
21. + currents densities in ventricular myocytes of guinea pigs by chronic oxidant stess [J]. Acta Pharmacol Sin, 2004, 25:751-755.
22. + channels [J]. Circ Res, 1998, 82:386-395.
23. Lees-Miller JP, Duan Y, Teng GQ, et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes : involvenment of S6 sites [J]. Mol Pharmacol, 2000, 57:367-374.
24. Ulens C, Tytgat J. Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation [J]. FEBS Lett, 2000, 474:111-115.
25. Yang BF, Dong DL, Li Z, et al. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related gene ( HERG ) channels [J]. Basic Clin Pharmacol Toxicol, 2004, 94:209-212.
26. Bril A, Gout B, Bonhomme M, et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872 [J]. J Pharmacol Exp Ther, 1996, 276:637-646.
27. Magyar J, Banyasz T, Fulop L, et al. Effects of the antiarrhythmic agent EGIS-7229 (S21407) on calcium and potassium currents in canine ventricular cardiomyocytes [J]. Naunyn Schmiedebergs Arch Pharmacol, 2001, 363:604-611.
28. Thomas D, Wimmer AB, Wu K, et al. Inhibition of human ether-a-go-go-related gene potassium channels by the al-adrenoceptor antagonists prazosin, doxazosin, and terazosin [J]. Naunyn Schmiedebergs Arch Pharmacol, 2004, 369:462-472.
29. Karle CA, Kreye VAW, Thomas D, et al. Antiarrhythmic drug Carvedilol inhibits HERG potassium channels [J]. Cardiovasc Res, 2001, 49:361-370.
30. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome : pharmacological treatment [J]. J Am Coll Cardiol, 2004, 43:1494-1499.
31. Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG [J]. Cardiovasc Electrophysiol, 2005, 16:54-58.
32. Li BX, Yang BF, Zhou J, et al. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes [J]. Acta Pharmacol Sin, 2001, 22:125-131.
33. 2+], in guinea pig ventricular myocytes [J]. Acta Pharmacol Sin, 2001, 22:512-515.
34. + current in guinea pig ventricular myocytes [J]. Acta Pharmacol Sin, 1998, 19:269-272.
35. Yang BF, Zhang Y, Du J, et al. Effects of matrine, oxymatrine and resveratrol on HERG channel expression [J]. Acta Pharm Sin, 2007, 42:139-144.
36. + channel long-QT2 mutations: human ethera-go-go-related gene rescue without block [J]. Circulation, 2002, 105:2830-2835.
37. + channel [J]. Mol Pharmacol, 2005, 67:827-836.
38. Zhou J, Augelli-Szafran CE, Bradley JA, et al . Novel potent hERG potassium channel enhancers and their in vitro antiarrhythmic activity [J]. Mol Pharmacol, 2005, 68:876-884.